^
    2d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    7d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=52, Enrolling by invitation, Janssen Research & Development, LLC | N=35 --> 52
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    9d
    Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks. (PubMed, Eur J Haematol)
    This study provides a pragmatic, consensus-driven framework for FD BTKi-venetoclax therapy in CLL, emphasizing patient selection and logistical feasibility. The work lays the groundwork for more rigorous evaluation of human-AI collaboration in the still-complex landscape of first-line CLL therapy.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Calquence (acalabrutinib)
    9d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=120, Enrolling by invitation, Janssen Research & Development, LLC | N=80 --> 120
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    9d
    Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of California, Davis | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    13d
    Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    14d
    Suspected Secondary Intraocular Lymphoma With Choroidal Involvement Following Testicular Diffuse Large B-cell Lymphoma: A Case Report. (PubMed, Cureus)
    Treatment with oral ibrutinib 560 mg daily was associated with clinical stability over 24 months, improvement of visual acuity to 20/40, resolution of subretinal fluid, stable residual choroidal changes, and no evidence of systemic recurrence. This case highlights the importance of long-term ophthalmic surveillance in patients with testicular DLBCL and the integration of multimodal imaging, ocular fluid analysis, and systemic restaging in the evaluation of suspected ocular relapse.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    Imbruvica (ibrutinib)
    14d
    Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability. (PubMed, Cancer Med)
    Ibrutinib is used clinically to treat specific B cell disorders; however, it is not currently approved to treat solid tumours. Data presented in OCCC cell lines complements clinical observations of a therapeutic response to ibrutinib in low-grade serous ovarian cancer. Ibrutinib demonstrates potential for the treatment of certain rare subtypes of ovarian cancer and should be further investigated.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A)
    |
    PIK3CA mutation • ARID1A mutation
    |
    Imbruvica (ibrutinib)
    14d
    Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors. (PubMed, Sci Transl Med)
    Pharmacological activation of WASp by its selective small-molecular activator EG-011 restores the ibrutinib-impaired TAM engulfment of tumor cells and effectively improves ibrutinib efficacy in mice bearing glioblastomas, primary central nervous system lymphomas, and lung carcinoma brain metastases. Furthermore, elevated expression of phosphorylated BTK or phosphorylated WASp in TAMs correlates with an increased phagocytic TAM subset identified by single-cell RNA sequencing and correlates with prolonged patient survival in a cohort with glioblastoma. Our preclinical study highlights the necessity of evaluating the on-target, off-tumor attack of TAMs during TKI administration and provides a proof of concept for reinvigorating the TAM phagocytic function to achieve additional clinical benefit.
    Preclinical • Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Imbruvica (ibrutinib)
    15d
    Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=19, Completed, University of California, Davis | Recruiting --> Completed | Trial primary completion date: Feb 2025 --> Jul 2025
    Trial completion • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Blincyto (blinatumomab)
    15d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC | Trial completion date: Jan 2028 --> Oct 2028
    Trial completion date
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    16d
    Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=42, Completed, Jennifer Woyach | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    Chr del(11q)
    |
    Imbruvica (ibrutinib)